Production (Stage)
Conduit Pharmaceuticals Inc.
CDT
$2.33
-$0.14-5.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.49% | 98.85% | 439.07% | 136.88% | 86.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.67% | 96.91% | 1,158.37% | 138.78% | 95.05% |
| Operating Income | -35.67% | -96.91% | -1,158.37% | -138.78% | -95.05% |
| Income Before Tax | -44.88% | -1,082.04% | -346.13% | -155.60% | -112.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.88% | -1,082.04% | -346.13% | -155.60% | -112.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.88% | -1,082.04% | -346.13% | -155.60% | -112.44% |
| EBIT | -35.67% | -96.91% | -1,158.37% | -138.78% | -95.05% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.47% | -742.56% | -284.73% | -123.68% | -85.96% |
| Normalized Basic EPS | 69.02% | -999.86% | -262.05% | -123.68% | -85.96% |
| EPS Diluted | 72.47% | 41.25% | -1,224.40% | -123.68% | -73.02% |
| Normalized Diluted EPS | 69.02% | -1,022.81% | -263.84% | -127.83% | -87.10% |
| Average Basic Shares Outstanding | 426.63% | 52.84% | 33.25% | 14.27% | 14.15% |
| Average Diluted Shares Outstanding | 426.63% | 48.99% | 31.80% | 12.18% | 13.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |